MindMed

Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co-founder and CEO, would step down. Benzinga spoke with Rahn on what the transition means for MindMed, the industry ...

Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a leading medicine biotech company in psychedelics, this week began trading on the Nasdaq exchange. In light of the momentous occasion, Benzinga spoke with MindMed co-founder and CEO J.R. Rahn, as well as board member Kevin O’Leary...

Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after submitting an application to uplist its shares from Toronto’s NEO exchange, MindMed (OTCQB: MMEDF) confirmed it will commence trading on the Nasdaq Capital...

MindMed Posts 2020 Financials, New MDMA Dosing Study and 18-MC Patent Application MindMed (OTCQB:MMEDF) released its full-year 2020 financial results.  The company posted a net and comprehensive loss of $35.1 million for the year ended Dec. 31, 2020. Its total assets at the end of the...

Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelics Industry News Stories for the Week of March 29th – April 4th, 2021. Without further ado...

Psychedelic medicine biotech company MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) reported Monday the results of a study on MDMA dosing optimization utilizing personalized medicine. The study was conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland. The company said it...

Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelics Industry News Stories for the Week of March 22nd – 28th, 2021. Without further ado,...

These days, the psychedelics finds itself in the midst of a public debate around the moral implications of patents and intellectual property for certain medicines and treatments. The conversation began last month when Compass Pathways (NASDAQ: CMPS) introduced a series of patent...

TILT Hires Two Compliance Experts TILT Holdings Inc. (CSE: TILT) (OTCQX: TLLTF) strengthened its leadership team by welcoming Nicole Moyers as vice president of compliance and Patrick Beyea as director of compliance. Moyers has extensive experience in government affairs, public service...

MindMed (NEO: MMED) (OTCQB: MMEDF) agreed to buy HealthMode, an artificial intelligence medicine company, in a CA$41.56 million (US$32.5 million) stock and cash deal. The psychedelic biotech company confirmed Thursday it will acquire a digital medicine and therapeutics startup that relies...

Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit.  The proceeds...

On January 27, the Horizons Psychedelic Stock Index ETF (NEO:PSYK) became the first exchange traded fund to focus solely on the psychedelics industry.  Horizons ETFs CEO Steve Hawkins sat down with Benzinga to discuss the listing, which brought in approximately CA$25 million ($19.4 million) in...